Infor, the industry cloud company, today announced that Sanford Health, the largest rural health care system in the United States serving more than 1.4 million patients, will implement a suite of Infor cloud-based applications designed for healthcare to streamline and modernize functions across its network. The integrated health system has 48 medical centers, 211 clinic locations, more than 160 Good Samaritan Society senior living centers, 2,900 Sanford physicians and advanced practice providers, 540 active clinical trials and nine world clinic locations around the globe. With Infor, Sanford Health will be able to better leverage data to break down silos across departments, streamline workflows, and gain real-time insights, freeing up caregivers to prioritize care.

Sanford Health decided to partner with Infor because of its modern, cloud-based architecture, and ability to offer health care-specific finance and supply chain solutions that meet the organization’s requirements without extensive manual customization. In addition, Infor’s solutions integrate seamlessly into Sanford’s current business needs and processes, providing leadership with real-time data. Lastly, Infor was able to clearly demonstrate its commitment to health care, extensive product roadmap, and forward-thinking approach.

Infor Healthcare offers industry specialized applications that provide one source of truth, with cloud flexibility, anytime, anywhere access, a beautiful user interface and healthcare-specific analytics. Its innovative system has the capabilities to unify processes across the employee lifecycle while seamlessly integrating with the core enterprise financial management and payroll solutions.

“We look forward to supporting Sanford Health in achieving greater operational efficiency and delivering exceptional health care services to the communities they serve,” said Steve Fanning, senior vice president, Infor.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Infor, Sanford Health Team Up to Unify Critical Cloud Applications first appeared on AI-Tech Park.

Funding will support expanded commercialization efforts for PreciseBreast risk assessment

PreciseDx®, a leading innovator in oncology diagnostics leveraging Artificial Intelligence (AI) for new, morphology-driven disease analysis, today announced that it has raised $20.7 million in Series B funding, bringing its total funding to date to $31.5 million. The round was led by Eventide Asset Management (“Eventide”), which invests in biotech and life science healthcare companies seeking solutions for unmet clinical needs.

Additional participants in the round include Labcorp, Quest Diagnostics, and GenHenn Capital Venture, along with existing investors.

“Our team continues to advance breast cancer diagnostics by delivering faster, more accurate data, in a cost-efficient method. This allows clinical care teams to make better informed clinical decisions resulting in improved patient outcomes,” said Eric Converse, Founding Board Member of PreciseDx. “This capital infusion sets the stage for our next phase of continued in-depth clinical trials to validate PreciseBreast in a specific clinical setting and market entry point.”

“We’re excited about PreciseDx, the milestones accomplished to date, and the potential for improving patient care in the near future,” said Westley Dupray, CFA, Research Analyst, Principal at Eventide. “We expect this financing will help accelerate the validation process for PreciseBreast and its potential to improve patient risk assessments, clinical outcomes, and healthcare efficiency.”

The funding comes on the heels of a number of key achievements by PreciseDx, including completion of two successful validation studies (analytical and clinical); receipt of CLIA Standard approval and CLEP NYSDOH review on the PreciseBreast assessment; a Cost Impact Study published by the Journal of Medical Economics; and the addition of new key collaborations, such as UCLA, COTA and Baptist Health South Florida, and Baylor Scott & White Health.

“Securing Series B funding not only signals PreciseDx’s continued achievements, but also underscores the trust and confidence in the Company’s trajectory,” added Converse.

Aquilo Partners, L.P. acted as financial advisor and McDermott Will & Emery as legal advisor to PreciseDx.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post PreciseDx Secures $20.7 Million Series B first appeared on AI-Tech Park.

Accelerating clinical trial development and discovering potential novel treatments for neurological, psychiatric and infectious diseases

DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, announces it is expanding the use of its novel BRAIN AGE® Brain Health AI Platform (“BRAIN AGE®”) through leveraging its electroencephalograph (“EEG”) data from research studies and future data collection, and applying it to build a potential drug discovery and clinical research AI platform. EEG provides a real-time readout of brain-wave activity in different brain regions and can measure a drug effect on the brain. BRAIN AGE® has the potential to accelerate patient recruitment for clinical trials, data analysis, drug development go/no-go decisions and new treatment options for neurological, psychiatric and infectious diseases.

BRAIN AGE® Brain Health AI estimates brain age by recording brain-wave activity from multiple brain regions and calculating the data with a proprietary machine-learning model. Certain drugs acting on the brain can generate a consistent EEG effect and produce models useful for developing novel drug analogs¹ and potential drug repurposing ideas. In studying the effects of drugs on the brain via EEG, researchers can classify and identify drugs according to their mechanism of action on brain activity.²

Clinical Validation of BRAIN AGE® Brain Health AI Platform

BRAIN AGE® Brain Health AI can assess if a brain is aging more quickly or more slowly than is typical for healthy individuals. Brain age is estimated by collecting neural activity data of the brain with a low-cost and easy-to-use electroencephalogram headset and calculating the data with a proprietary machine-learning model. In addition, BRAIN AGE® Brain Health AI can assess if a person has a healthy brain or is in the early stage of cognitive decline. Brain health is scored by taking a clinically validated assessment for brain resilience, vulnerability and performance functions. Individuals can seek out personalized diagnostics and interventions, such as medication or lifestyle changes, that may help decrease cognitive decline development or progression.

In a first-of-a-kind peer-reviewed paper in Frontiers in Neuroergonomics, titled “Brain-age estimation with a low-cost EEG-headset: effectiveness and implications for large-scale screening and brain optimization”³, BRAIN AGE®, as announced in a press release by Drexel University, Prof. Kounios was quoted regarding the clinical potential of BRAIN AGE®: “It can be used as a relatively inexpensive way to screen large numbers of people for vulnerability to age-related. And because of its low cost, a person can be screened at regular intervals to check for changes over time,” Kounios said. “This can help to test the effectiveness of medications and other interventions. And healthy people could use this technique to test the effects of lifestyle changes as part of an overall strategy for optimizing brain performance.”⁴

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post DiagnaMed Expands with Drug and Clinical Research AI Platform first appeared on AI-Tech Park.

Clinical Services provides clinical trial and laboratory supply chain services to pharmaceutical and biotechnology companies, contract research organizations (CROs), and diagnostic laboratories. The business operates 10 facilities across the US, UK, and Europe. It also maintains a global logistics and equipment services network that distinguishes the business as a partner of choice to help its clients manage complex and evolving supply chain needs.

“We appreciate the unique capabilities that this business delivers to some of the most demanding customers in the pharma and life sciences sectors, and we look forward to investing aggressively to expand the Company’s commercial and technical reach,” said David Wong, Partner at Audax Private Equity. “We believe the services that this business provides represent the backbone for advancing therapeutic development.”

The Company provides active trial and post-trial sample storage and archiving, supply chain management, and packaging and logistics for sample collection through three primary offerings and well-respected brand names: EPL Archives, MESM, and Therapak.

Audax has completed several corporate carveouts in the past, including the acquisitions of Aspen Surgical, Lifemark, and others. The firm also brings deep experience in the healthcare space, with a portfolio that includes companies in pharma services, life science tools, medical technology, and value-based care.

“We’re pleased to work with Avantor to effect a quick and seamless transition to the benefit of all of our stakeholders,” added Stephen Weaver, Managing Director at Audax Private Equity. “The investments we intend to make to this platform should deliver tremendous benefit to our clients and our team members.”

Audax is investing through its flagship fund.

Moelis & Company LLC served as financial advisor and Ropes & Gray LLP served as legal counsel to Audax Private Equity. J.P. Morgan Securities LLC served as financial advisor to Avantor and Arnold & Porter served as Avantor’s legal advisor.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Audax Private Equity to Acquire Avantor’s Clinical Services Business first appeared on AI-Tech Park.

Veridix AI, part of Emmes Group, a specialty tech and AI enabled CRO, today announced the launch of their new protocol digitization capabilities. This advanced capability lays the foundation to accelerate the clinical trial study build process by up to 30%.

Built within Veridix AI’s unified eClinical platform, Advantage eClinical Cloud, this new approach utilizes natural language processing (NLP) techniques in combination with AI, to digitize clinical trial protocols into structured data elements such as visit schedules, cohorts, and eCRFs. Trained and optimized from prior clinical trial data, the approach enables automated generation of visit schedules and provides a list of predicted eCRFs with 82%+ accuracy.

Clinical trial processes have been plagued by slow, manual, error-prone processes. Reviewing a protocol to determine elements required for study builds is no exception. This new approach presents a concrete application of AI techniques to accelerate clinical trials and improve data quality.

“Protocol digitization has the potential to reshape how protocol information is used throughout the clinical research process and ecosystem. Powered by NLP and AI technologies, we are automating more of the clinical trial process. This is just one example of how we’re embedding more technology and AI within the clinical research process,” said Rama Kondru, chief executive officer, Veridix AI.

Upcoming releases for Advantage eClinical Cloud will provide an embedded workflow for transforming protocols into structured data elements, and ultimately automated creation of eCRFs and associated edit checks based on AI predictions.

“This unique capability allows us to accelerate the study build process and allows our data managers to focus on value added work rather than manual, tedious processes,” said Sastry Chilukuri, chief executive officer, Emmes Group. “We’re already deploying this capability across more than 40 new study builds in both our government and commercial portfolio,” added Chilukuri. “This highlights our commitment to improving clinical trials by applying next generation technology and AI capabilities.”

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Veridix AI Announces New Protocol Digitization Capabilities first appeared on AI-Tech Park.

Tidewater Clinical Research has been successfully acquired by Eximia Research Network. This acquisition marks a significant milestone as Eximia continues expanding its national clinical trial site network. 

Since its founding in 1994, Tidewater Clinical Research has led advancements in Women’s Health and Ophthalmology through clinical trials in the Hampton Roads/Eastern Virginia region. This integration will combine Tidewater’s robust expertise and patient database with Eximia’s extensive resources and clinical trial experience.

“Tidewater Clinical Research is proud to announce our integration into the Eximia Research Network, marking a significant step forward in enhancing clinical research accessibility and quality of care for diverse patient populations,” says Tidewater owner Kelley Fleming. Tidewater co-owner April Rusch adds, “Under the Eximia umbrella, Tidewater is poised to broaden its impact on patient health and contribute to the advancement of medical research in ever-expanding medical subspecialty areas.”

Eximia is equally enthusiastic about joining forces with Tidewater: “We are excited to welcome Tidewater Clinical Research to the Eximia network,” said Dr. Ella Grach, CEO of Eximia Research Network. “Their expertise in Women’s Health and Ophthalmology complements our mission to drive innovation and improve patient outcomes. This acquisition enhances our ability to serve diverse populations and support groundbreaking clinical research nationwide.”

Advisors David Bogart and Devak Patel from Viking Mergers & Acquisitions facilitated the transaction. Tidewater praised Viking’s role in the process. “David and Devak from Viking were great to work with.” According to both owners, “The team at Viking gave us great advice and counsel at every stage of the acquisition process, and ultimately, they found a great buyer in Eximia for Tidewater.”

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Tidewater Clinical Research Acquired by Eximia Research Network first appeared on AI-Tech Park.

Today, Jefferson and Lehigh Valley Health Network (LVHN) announced the close of the transaction making them one health system. The combination creates a leading integrated academic health care delivery system, alongside a national doctoral research university and an expanded not-for-profit health plan.

The system is now among the top 15 not-for-profit health systems in the U.S. with 32 hospitals and more than 700 sites of care, which will increase patient access to high-quality and affordable care, clinical research and health plan offerings while addressing health inequities for urban and rural communities in Eastern Pennsylvania and Southern New Jersey.

“We are delighted to bring these two incredible organizations together as we look ahead at all the good we will do for the communities we’re privileged to serve,” said Joseph G. Cacchione, MD, Chief Executive Officer, Jefferson. “This milestone is even more significant as Jefferson celebrates its bicentennial, marking our longstanding commitment to improving lives through education, health care and discovery. As we create our third century, this is a historic moment for our 65,000 colleagues as it marks a new chapter in access, innovation, equity, and opportunity for patients, students and health plan members. We have many more milestones ahead as we share knowledge and integrate our operations.”

“As health care continues to rapidly evolve, two leading health care organizations are forging ahead to build a bright future for health care in our communities,” said Brian A. Nester, DO, MBA, now serving as Executive Vice President/Chief Operating Officer of the Jefferson enterprise with oversight of the legacy Lehigh Valley Health Network, reporting to Dr. Cacchione. “Our combination will enhance access and elevate service by bringing more specialists, locations, expertise, research and education to the patients and communities we serve.”

With the transaction complete, LVHN is now proudly part of Jefferson Health. Cacchione will continue to serve as Chief Executive Officer of the Jefferson enterprise. He is joined on the leadership team by Baligh R. Yehia, MD, who will serve as President of the legacy Jefferson Health and Executive Vice President/Chief Transformation Officer of the Jefferson enterprise. The newly integrated Board of Trustees and leadership team is comprised of members from both systems.

“The combination of our two world-class health care institutions will allow us to set the course for care in the region by launching new clinical programs, advancing health equity and building healthier communities,” said Dr. Yehia. “Jefferson Health and Lehigh Valley Health Network will work together to recruit and retain the best and brightest clinicians, offering them opportunities to advance their careers while providing exceptional care and exemplifying our unwavering commitment to improving the health and well-being of the communities we serve.”

The combined organization will focus on integrating clinical care, operations, and brand identity to create a regional system that delivers the highest quality care to those it serves. Moving forward, patients will have seamless access to a broader network of specialists who will collaborate and innovate to bring groundbreaking technology and treatments close to home, as both legacy organizations have done for a combined 325 years. Ultimately, patients will benefit from continuous research that translates to groundbreaking clinical trials, improving treatment outcomes.

At the same time, the expanded organization will offer current and future clinicians new educational and development opportunities across its larger service areas and will leverage its position as a world-class medical institution to recruit the best and brightest clinicians. Also, as part of the integration, the region LVHN serves will soon have access to Jefferson Health Plans, an expanded, affordable health plan option that will help vulnerable populations receive care to live well and stay out of the hospital.

The combined Jefferson-LVHN organization is committed to ensuring the patients and communities it serves continue to have access to exceptional care from their clinicians throughout the integration process and beyond. Patients will continue to see their physicians and care teams as they have been and will receive updates on additional offerings as available.

Jefferson and LVHN announced in December 2023 that they had signed a letter of intent to combine and reached a definitive agreement earlier this year.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Jefferson, Lehigh Valley Health Network Complete Combination first appeared on AI-Tech Park.

AI-enhanced solution will help Eisai accelerate data review and reconciliation by 80% 

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, today announced Eisai Inc. (“Eisai”), the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., as one of the first customers to harness its recently announced AI-driven Medidata Clinical Data Studio. Eisai Inc., will leverage this innovative data experience to gain unprecedented control over its clinical data, enable the execution of scalable and complex clinical trials, and enhance patient experience. 

“We’ve included Medidata’s Clinical Data Studio in our clinical trial management platform given its ability to break down data silos and seamlessly integrate into our current software stack, while maintaining quality and integrity across all data sources,” said Shobha Dhadda, Ph.D. chief clinical science & operations officer, at Eisai. “Having a suite of technology solutions capable of processing diverse clinical and patient data types provides increased efficiencies without sacrificing quality or needing additional resources.” 

Clinical Data Studio is powered by the Medidata Platform, the industry’s only unified platform that centrally manages all data sources, improving data reliability across the entire clinical trial ecosystem. By seamlessly integrating data from both Medidata sources, including Medidata Rave EDC, and non-Medidata sources, such as labs or another electronic data capture system, Clinical Data Studio streamlines the import process and enables automatic validation through configured data transfer agreements. Utilizing AI, it mitigates challenges posed by disparate data systems and offers up to 80 percent faster data review while providing a comprehensive view of patient data that can be concurrently reviewed, visualized, and acted on.  

“Through Clinical Data Studio, Eisai is enabling healthcare stakeholders to overcome the complexities of modern clinical trials and foster collaboration on cleaner, more actionable data,” said Janet Butler, executive vice president, global head of sales, Medidata. “By delivering a unified AI-driven data management and analytics experience, we are enabling study teams to identify potential data issues faster and gain a more accurate understanding of the patient.” 

About Medidata 
Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 33,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,200+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata. 

About Dassault Systèmes 
Dassault Systèmes is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients and citizens. Dassault Systèmes brings value to more than 350,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com 

© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries. All other trademarks are owned by their respective owners. Use of any Dassault Systèmes or its subsidiaries trademarks is subject to their express written approval. 

About Eisai Inc. 

Eisai Inc., a human health care company, is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd. headquartered in Nutley, N.J. Dedicated to oncology and neurology, its U.S. operations include research & development; manufacturing; global supply & logistics; and commercial activities. Learn more: https://us.eisai.com; Follow us on X and LinkedIn. 

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Eisai Chose Medidata Clinical Trial Studio for Efficient Clinical Trial first appeared on AI-Tech Park.

Datavant will feature groundbreaking AI innovations in clinical trials, demonstrating the potential of artificial intelligence to transform patient outcomes and operational efficiencies. This showcase will be conducted in partnership with Premier, Inc. leveraging their extensive real-world data sets to enhance the development and execution of clinical trials.

“Participating in the Senate AI Showcase is a remarkable opportunity for us to demonstrate the revolutionary impact of AI on clinical trials,” said Kyle Armbrester, CEO at Datavant. “Our partnership with Premier enables us to harness diverse and comprehensive data sets, driving unprecedented innovation and significantly improving patient outcomes. We are at the forefront of a healthcare transformation that will set new standards in the industry.”

The event will bring together key stakeholders, including government officials, industry leaders, and healthcare experts, to discuss the advancements and applications of AI in healthcare. Attendees will have the opportunity to explore how AI is being utilized to develop new medicines, enhance disease detection and diagnosis, and assist healthcare providers.

To learn more about Datavant, visit datavant.com.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Datavant to participate at AI Demonstration Day on Capitol Hill first appeared on AI-Tech Park.

Barbara Lopez Kunz brings a wealth of experience to the role, having served in various leadership capacities across the healthcare and life sciences sectors. With over 15 years of C-suite experience and a proven track record in driving strategic partnerships and digital transformation, Ms. Kunz is well-prepared to lead Caidya into its next phase of growth and innovation.

Dr. Lingshi Tan expressed his enthusiasm for Ms. Kunz’s appointment, stating, “Barbara’s leadership capabilities and profound understanding of the global healthcare landscape have been invaluable to our board. Her strategic vision and commitment to innovation have already significantly impacted our business. I have the utmost confidence in her ability to steer Caidya towards a successful future. I am thrilled she has accepted this expanded role and look forward to working closely with her.”

In her new role, Ms. Kunz will focus on enhancing Caidya’s position as a global leader in clinical research, emphasizing the importance of patient-centered trials and building personalized, fit-for-purpose solutions. “I am honored to lead Caidya and build on the strong foundation laid by Dr. Tan,” said Ms. Kunz. “Caidya’s commitment to transforming the landscape of clinical research resonates deeply with my professional philosophy.
I look forward to working closely with Dr. Tan and our talented team to realize the strategic vision and continue our trajectory of innovation and growth.”

Barbara Lopez Kunz’s career as an executive leader is distinguished by her roles in catalyzing winning strategies for multinational corporations and non-profit organizations. She has held significant P&L responsibilities at major companies including Thermo Fisher Scientific, DuPont, and ICI (now AstraZeneca), as well as at non-profits like Battelle and DIA. Her leadership style, characterized by a focus on clear strategic direction, people development, and learning agility, has cultivated strong teams and innovative practices throughout her career. Ms. Kunz also brings decades of experience serving on public, private, and non-profit boards, where she has been instrumental in transformative strategies, enhancing shareholder value.

Reflecting on her appointment to the Caidya Board in November 2022, Ms. Kunz expressed her excitement to contribute her deep expertise in the life sciences industry to enhance Caidya’s innovativeness, build productive partnerships, and develop talent as Caidya executes its global growth strategy. Her dedication to creating a people- and patient-first culture is well aligned with Caidya’s corporate values. As Caidya continues to evolve and expand its global impact, Barbara’s leadership will be instrumental in driving forward the company’s purpose of helping to bring life-changing therapies to the global community through liberated clinical research.

For more information about Caidya and its services, please visit www.caidya.com.

Explore AITechPark for the latest advancements in AI, IOT, Cybersecurity, AITech News, and insightful updates from industry experts!

The post Caidya Announces Leadership Transition: Barbara Lopez Kunz Named CEO first appeared on AI-Tech Park.